This week’s headlines include: AbbVie Launches, Biogen Tweaks Alzheimer’s Collaborations, BioMarin’s Gene Therapy for Hemophilia A Continues to Impress, Ventria Wins $4.2M Gates Foundation Grant toward Biomanufacturing ETEC Therapeutics, The Long War on Polio, as Recalled by Its Generals, Biogen takes up option to co-develop Eisai AD drug, and Will FDA Add Suffixes to Approved Biologics’ Names?
In Case You Missed It, Recent Articles on Cell Culture Dish and Downstream Column:
Do you have to sacrifice antibody titer for quality? Employing cell biology to get the best of both worldsIn this podcast and accompanying article, we interviewed Dr. Adam Elhofy, Ph.D., Chief Scientific Officer, Bio-Ess Laboratories, about the relationship between antibody titer and product quality attributes such as glycosylation. Dr. Elhofy shares his thoughts on both challenges and opportunities in optimizing for both high titer and glycosylation profiles…
Cool Tool – ‘Jetting’ technology for manufacturing agarose beads with enhanced performance characteristicsThe vast majority of chromatography resins designed for large-scale bioprocess chromatography separation are produced using traditional batch emulsification in conventional stirred-tank reactors. In these cases, the size of the beads formed in the reactor is a function of the shear force generated by the impeller. The faster the impeller speed, the smaller the beads are. As a result, there is a wide particle size distribution of the manufactured beads. Furthermore screening is required to remove coarse and fine beads, which detract from column performance. This screening is extremely time consuming particularly for smaller beads (less than 65 µm). The smaller the bead being produced the lower the achieved yield so realistically one cannot make beads financially viable less than 40 µm. It also adds high costs due to the additional time in the manufacturing facility with large volumes of waste from the fine and coarse beads. Even after this screening, the resin will still have a relatively wide size particle distribution…
November3rd Annual Cell & Gene Therapy Congress November 6 – November 7 immarsat, 99 City Road London, EC1Y 1AX United Kingdom Oxford Global Conferences presents its 3rd Annual Cell & Gene Therapy Congress, with our co-located 6th Annual Cell Culture & Bioprocessing Congress and 4th Annual Stem Cell Congress and, 6 – 7 of November 2017, London, UK. Cell & Gene Therapy: Development & Clinical Trials Cell Therapy Bioprocessing and Manufacturing Presentations will include cell & Gene Therapy development, updates in regulatory pathways, commercialisation, bioprocessing and manufacturing. World Orphan Drug Congress Europe November 13 – November 15 FAIRMONT REY JUAN CARLOS I, Av. Diagonal, 661-671 BARCELONA, 08028 Spain The 8th annual World Orphan Drug Congress is the marketplace for orphan drug professionals looking at the complete value chain of orphan drug development, from clinical development and R&D to corporate development and market access.
“Ventria Wins $4.2M Gates Foundation Grant toward Biomanufacturing ETEC Therapeutics,” Genetic Engineering News“Ventria Bioscience said today it has won a $4.2 million grant from the Bill & Melinda Gates Foundation toward the biomanufacturing of new therapeutics targeting enterotoxigenic Escherichia coli (ETEC). Ventria said the grant will enable it to develop its ExpressTec technology platform for producing potential ETEC treatments…”
“Coffee With Polio Experts” will not be picked up by Hulu anytime soon, but there is something compelling in these short videos put out by the Global Polio Eradication Initiative. The formula is simple: Doctors who have spent years fighting polio in the world’s most remote regions sit down over coffee with a World Health Organization representative to tell war stories…”“Back in January, the US Food and Drug Administration (FDA) finalized guidance on how biosimilars and their biologic reference products’ names should include a four-letter, FDA-designated meaningless suffix attached at the end of the nonproprietary name…”